Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.
Sphingosine 1-phosphate (S1P) plays important roles in cell proliferation, differentiation or survival mainly through its surface G-protein-coupled receptors S1P1-5. Bone represents the major site of metastasis for prostate cancer (CaP) cells, which rely on bone-derived factors to support their proliferation and resistance to therapeutics. In the present work we have found that conditioned medium (CM) from the MC3T3 osteoblastic cell line or primary murine and human osteoblast-like cells, as well as co-culture with MC3T3 stimulate proliferation of CaP lines in S1P-dependent manner. In addition, osteoblastic-derived S1P induces resistance of CaP cells to therapeutics including chemotherapy and radiotherapy. When S1P release from osteoblastic cells is decreased (inhibition of SphK1, knock-down of SphK1 or the S1P transporter, Spns2 by siRNA) or secreted S1P neutralized with anti-S1P antibody, the proliferative and survival effects of osteoblasts on CaP cells are abolished. Because of the paracrine nature of the signaling, we studied the role of the S1P receptors expressed on CaP cells in the communication with S1P secreted by osteoblasts. Strategies aimed at down-regulating S1P1, S1P2 or S1P3 (siRNA, antagonists), established the exclusive role of the S1P/S1P1 signaling between osteoblasts and CaP cells. Bone metastases from CaP are associated with osteoblastic differentiation resulting in abnormal bone formation. We show that the autocrine S1P/S1P3 signaling is central during differentiation to mature osteoblasts by regulating Runx2 level, a key transcription factor involved in osteoblastic maturation. Importantly, differentiated osteoblasts exhibited enhanced secretion of S1P and further stimulated CaP cell proliferation in a S1P-dependent manner. By establishing the dual role of osteoblast-borne S1P on both osteoblastic differentiation and CaP cell proliferation and survival, we uncover the importance of S1P in the bone metastatic microenvironment, which may open a novel area of study for the treatment of CaP bone metastasis by targeting S1P.
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France.
Leyre
L
Brizuela
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France.
Claire
C
Martin
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France.
Pauline
P
Jeannot
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France.
Isabelle
I
Ader
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France.
Cécile
C
Gstalder
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France.
Guillaume
G
Andrieu
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France.
Magalie
M
Bocquet
Université de Toulouse, UPS, IPBS, Toulouse, France; CHU Toulouse, Service d'orthopédie et Traumatologie, Toulouse, France.
Jean-Michel
JM
Laffosse
Université de Toulouse, UPS, IPBS, Toulouse, France; CHU Toulouse, Service d'Anatomopathologie, Toulouse, France.
Anne
A
Gomez-Brouchet
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France; CHU Toulouse, Service d'Urologie et de Transplantation Rénale, Toulouse, France.
Bernard
B
Malavaud
Lpath Inc., San Diego, CA, USA.
Roger A
RA
Sabbadini
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France; Université de Toulouse, UPS, IPBS, Toulouse, France; Equipe Labellisée Ligue contre le Cancer, France. Electronic address: olivier.cuvillier@inserm.fr.
Olivier
O
Cuvillier
D000818:Animals; D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D018920:Coculture Techniques; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008246:Lysophospholipids / Q000378:metabolism*; D008297:Male; D051379:Mice; D010006:Osteoblasts / Q000166:cytology / Q000473:pathology*; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D049349:Receptors, Lysosphingolipid / Q000378:metabolism*; D015398:Signal Transduction; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000378:metabolism
D008246:Lysophospholipids; D049349:Receptors, Lysosphingolipid; C060506:sphingosine 1-phosphate; D013110:Sphingosine
Differentiation; Docetaxel; Osteoblasts; Radiotherapy; Sphingomab; Sphingosine kinase